Kornimate/medical-research-clean huggingface dataset:
novel sars-cov-2 point-of-care testing

Conditions: SARS-CoV2 Infection

Summary: the aim of the project is to study the feasibility of implementing a novel point-of-care test (poct) for rapid detection of sars-cov-2 infection. a crispr-based detection kit would be piloted for testing of suspected sars-cov-2 infection in healthcare setting, with the objectives of evaluating the performance of the new test in the detection of sars-cov-2, and assessing the practicability of the new test for diagnosing sars-cov-2 infection in healthcare settings.

a crispr-based lateral flow assay (lfa) detection kit would be designed and developed for testing for the presence of sars-cov-2. the aim of the project is to study the feasibility of implementing the novel point-of-care test (poct) for rapid detection of sars-cov-2 infection in health service setting, with the following objectives: (b) evaluation of the performance of novel poct in comparison with conventional quantitative pcr in diagnosis sars-cov-2 infection and (c) assessment of the practicability of lfa-crispr-based tests in the operating environments in healthcare settings. patients who are admitted to the isolation wards of prince of wales hospital, hong kong would be invited to join the study. a total of 600 persons with suspected sars-cov-2 infection presenting with different symptomatology and epidemiological history will be recruited. nasal, deep saliva and/or mouth gargle samples will be collected from all recruited subjects in accordance with standard clinical protocol. the samples would be tested for sars-cov-2 by the new point-of-care test, in parallel with standard diagnostic testing of the hospital.

Eligibility criteria:
inclusion criteria: * adult patients admitted to isolation wards of the hospital who are * of age of 18 or above; * presentation with symptoms of covid-19 and/or * demonstration of exposure risk to sars-cov-2 infection. exclusion criteria: * inability to communicate in english or chinese; * known history of mental illness; * prisoners.

Keywords: sars-cov-2 point-of-care testing rapid diagnostics hong kong
physiological-based pharmacokinetics approach to medication exposure during pregnancy and breastfeeding

Conditions: Epilepsy; Pregnancy Related

Summary: this project focuses on anti-seizure medication (asm) clearance and physiological factors determining blood concentrations in pregnant adult women with epilepsy and amounts of exposure to their unborn children and nursing infants.

the goal of this study is to develop modeling of pharmacokinetic changes for antiseizure medications (asms), lamotrigine (ltg), and levetiracetam (lev) during pregnancy and postpartum that can be used to: 1. adjust doses in practice without obtaining frequent visits to the lab for therapeutic drug monitoring. 2. predict exposure of asms in mothers and their infants in order to maintain the individualized target concentrations, thus protecting mothers from seizure worsening and minimizing fetal toxicity. hypotheses: 1. drug concentrations obtained in preconception and early pregnancy predict clearance changes throughout the remainder of pregnancy for individual pregnant women with epilepsy. 2. validated model allows the prediction of drug concentration changes at all stages throughout and after pregnancy, which will more accurately predict increased seizures and medication side effects. additionally, pilot data will be obtained for oxcarbazepine (oxc) in a small number of participants and contribute to data for asms that undergo glucuronidation (ltg).

Eligibility criteria:
inclusion criteria: * woman with epilepsy between the ages of 18-45 planning pregnancy or in the early first trimester of pregnancy. * women with epilepsy ability to maintain a daily medical diary * women with epilepsy ability to answer side effect questionnaires * women with epilepsy currently being treated with lamotrigine (ltg) or levetiracetam (lev) or oxcarbazepine (oxc) exclusion criteria: * women with epilepsy having history of functional seizures. * women with epilepsy history of other major medical illnesses including renal or hepatic disease, progressive cerebral disease, * women with epilepsy who have inability to maintain a seizure and medication daily diary * women with epilepsy with present or recent history of drug or alcohol abuse, or the use of any concomitant medications that interact with the asm they are taking (lamotrigine, levetiracetam, oxcarbazepine).
comparison of nexavar/placebo as maintenance therapy for patients with advanced ovarian or primary peritoneal cancer

Conditions: Ovarian Neoplasms

Summary: comparison of nexavar with a placebo as maintenance therapy for patients with advanced ovarian or primary peritoneal cancers in complete remission following surgery and one regimen of chemotherapy.


Eligibility criteria:
inclusion criteria: * histologically confirmed international federation of gynecology and obstetrics (figo) stage (67) iii or iv ovarian epithelial cancer or primary peritoneal cancer at presentation. patients must have achieved a clinical complete response (disappearance of all clinical and radiological evidence of tumor) after only one regimen (4-6 cycles) of platinum and taxane-based standard chemotherapy received after tumor debulkment. * normal serum ca125 (cancer-associated tumor marker) level within 7 days of first dose of sorafenib. * eastern cooperative oncology group (ecog) performance status of 0 or 1. * all scans used to document complete response must be done within 30 days prior to randomization. * patients must be able to swallow and retain oral medication. exclusion criteria: * patients with any residual cancer tissue after the completion of chemotherapy detectable by standard computed tomography (ct) or magnetic resonance imaging (mri). * prior local radiotherapy, neoadjuvant chemotherapy or intraperitoneal chemotherapy. * histologic subtypes of ovarian cancer other than epithelial (i.e. sarcoma, lymphoma, germ cell). * major surgery, open biopsy, or significant traumatic injury within 30 days prior to randomization.

Keywords: peritoneal neoplasma
phase ii study of kwa-0711 in patients with chronic constipation (cc)

Conditions: Chronic Constipation

Summary: the purpose of this study is to evaluate the safety and efficacy of kwa-0711 in chronic constipation (cc) patients.


Eligibility criteria:
inclusion criteria: * the patients who experienced fewer than three spontaneous bowel movements (sbms) per week for more than 6 months prior to the enrollment * the patients who experienced one or more of the following signs or symptoms during more than 25% of bowel movements for more than 6 months: straining, lumpy or hard stools, and a sensation of incomplete evacuation exclusion criteria: * patients who have secondary constipation caused by systemic disorder * patients who have organic constipation * patients who received intestinal resection

Keywords: chronic constipation cc
gene expression profiling in a validation cohort of locally advanced and recurrent/metastatic salivary gland cancers

Conditions: Salivary Gland Cancer

Summary: the indaga-uk trial is a retrospective, multi-centre observational study in participants with locally advanced and recurrent salivary gland to investigate t its molecular profiling, and to explore new prognostic and druggable markers. we will analyse samples and data from patients diagnosed with salivary gland cancer from 2013 - 2023. subject and sample identification will occur over a 12-month period. samples and data will be analysed over the next 12 months prior to study end.


Eligibility criteria:
inclusion criteria: 1. aged over 18 2. histological diagnosis of salivary gland cancer (sgcs) 3. availability of archival tissue (acceptable after 2013 up to present) 4. ability to give informed consent (if applicable)\* for retrieving histological specimen and preform molecular analysis \*de-identified archival tissue from deceased patients will be collected as part of the study once rec approval is in place, if the patient was alive when the samples were taken and they are not part of the nhs opt out scheme. exclusion criteria: 1. different h\&n cancer of other histology 2. thyroid cancers
stepping stones program for preventing hiv infection in residents of rural south african communities

Conditions: HIV Infections

Summary: this study will evaluate the effectiveness of stepping stones, an hiv-prevention education program, versus a brief hiv-focused intervention, in improving sexual health and preventing hiv infection in young residents of rural south african communities.

hiv is arguably the most important problem currently facing the south african population. it is possible that biotechnology will eventually be able to lessen the disease's threat by introducing a vaccine or vaginal microbicide, but these are not expected to be available within the next 5 to 10 years. it is therefore extremely important to prevent hiv infection by modifying sexual behaviors. voluntary counseling and testing have been shown to have an important impact on sexual behavior, but it is essential that other approaches to hiv prevention are developed and evaluated. little research, however, has been done on behavioral interventions, relative to the amount of research that has been devoted to biotechnology development. stepping stones is an approach to hiv prevention that aims to improve sexual health through building stronger, more gender-equitable relationships with better communication between partners. this study will evaluate the effectiveness of the stepping stones program versus a brief hiv-focused intervention in improving sexual health and preventing hiv infection in young residents of rural south african communities. participants in this open-label study will be randomly assigned to take part in either the stepping stones program or the brief hiv-focused intervention (control). all participants will first attend a baseline study visit, which will include an interview and hiv testing. the control intervention will entail a single 2- to 3-hour meeting among same-sex peer groups, and will include exercises about hiv and safer sex practices that will be drawn from the stepping stones program. stepping stones will entail 17 sessions with same-sex peer groups, and will be implemented over a period of 3 to 12 weeks. sessions will involve discussions on a variety of sexual health issues, including the following topics: reflections on love; sexual health joys and problems; body mapping; menstruation; contraception and conception, including infertility; sexual problems; unwanted pregnancy; hiv; stds; safer sex; gender-based violence; motivations for sexual behavior; and dealing with grief and loss. peer groups will come together for 3 of the 17 meetings to build assertive communication skills by leading presentations on exercises from the stepping stones program. hiv testing will be performed again after 12 and 24 months to assess program effectiveness. face-to-face interviews will be held at months 6, 12, and 24 to assess the impact of the intervention on behavior, attitude, and beliefs.

Eligibility criteria:
inclusion criteria: * resident of the village in which individual is studying (i.e., not a migrant scholar) * mature enough to understand the study and the consent process exclusion criteria: * n/a

Keywords: behavioral intervention hiv hsv2
cholesterol-lowering effects of nutraceuticals versus ezetimibe in statin-intolerant patients

Conditions: Coronary Artery Disease

Summary: treatment with statins has a class i indication after percutaneous coronary intervention (pci), but is often discontinued by patients due to side effects. pharmacologic alternatives shown to be useful after pci include ezetimibe and nutraceuticals (i.e. compounds derived from foods with cholesterol lowering actions). it remains unknown, however, which of these two therapeutic approaches is more effective after pci. the primary objective of this study is to compare the efficacy and tolerability of ezetimibe vs. a nutraceutical-based protocol in statin-intolerant patients treated with percutaneous coronary intervention.

background treatment with statins has a class i indication after percutaneous coronary intervention (pci), but is often discontinued by patients due to side effects. pharmacologic alternatives shown to be useful after pci include ezetimibe and nutraceuticals (i.e. compounds derived from foods with cholesterol lowering actions). it remains unknown, however, which of these two therapeutic approaches is more effective after pci. purpose the primary objective of this study is to compare the efficacy and tolerability of ezetimibe vs. a nutraceutical-based protocol in statin-intolerant patients treated with percutaneous coronary intervention. study population patients with coronary artery disease in stable conditions treated with percutaneous coronary intervention who have withdrawn statin treatment due to side effects randomization patients will be randomized to receive for 6 months either ezetimibe (10 mg/day) or a commercially available nutraceutical combined pill (1 capsule/day containing monacolin k 10 mg, policosanol 10 mg, and phytosterols 300 mg).

Eligibility criteria:
inclusion criteria: * angiographically-proven coronary artery disease * recent (\<12 months) percutaneous coronary intervention * class i indication to receive statin treatment * previous (\<12 months) withdrawn of a statin due to side effects * unwilling to receive treatment with an alternative statin * able to understand and willing to sign the informed consent form exclusion criteria: • women of child bearing potential patients must demonstrate a negative pregnancy test performed within 24 hours before ct

Keywords: coronary artery disease
use of immediate hyperthermic intravesical chemotherapy following turbt

Conditions: Bladder Cancer; Hyperthermia; Chemotherapy Effect

Summary: this is a prospective single-arm pilot study investigating the safety and feasibility of giving hyperthermic intravesical chemotherapy immediately following transurethral resection of bladder tumour.

the combat bladder recirculation system (brs) is a ce marked device which has been used in over 200 sites in europe. it is an aluminum heat exchanger that allows hyperthermic intravesical chemotherapy (hivec) at 43±0.2 degrees for patients with bladder cancer. previous studies showed that the combat brs could warm the entire bladder wall to the target temperature with excellent safety parameters. the flow rates and pressure levels are kept low during the hivec treatment. a previous study has demonstrated the safety and tolerability of hivec as a maintenance therapy for patients with non-muscle-invasive bladder cancer (nmibc), and two randomized controlled trials are underway to demonstrate its efficacy in terms of disease recurrence and progression. on the other hand, the use of hivec immediately following transurethral resection of bladder tumour (turbt) remains largely unexplored. it is the investigators' current practice to give intravesical mitomycin c (mmc) to all patients who have endoscopically nmibc with complete resection, provided that there are no bladder perforations being noted. in this study, the investigators shall evaluate the safety and feasibility of hyperthermia in addition to the current practice of intravesical mmc alone immediately following turbt.

Eligibility criteria:
inclusion criteria: * 18 years or above with informed consent exclusion criteria: * ecog performance status ≥2 * asa 4 or above * history of bleeding disorder * any use of anti-coagulants * pregnancy

Keywords: hyperthermic intravesical chemotherapy bladder cancer
the corona study of middle norway

Conditions: SARS-CoV-2 Acute Respiratory Disease; SARS-CoV-2 Sepsis; SARS CoV 2 Infection

Summary: cut covid is a cohort study establised to collect information on patients hospitalized because or with infection by sars-cov-2. the cohort data includes clinical data and biological samples from multiple timepoints during hospitalization, as well as data from a followup consultation 3 months after discharge.


Eligibility criteria:
inclusion criteria: * positive sars cov-2 infection exclusion criteria: -
effects of hold relax with agonist contraction and active release therapy on clinical outcomes in piriformis syndrome

Conditions: Piriformis Syndrome

Summary: the aim of this study is to compare the effects of hold relax agonist contraction and active release therapy on reducing pain intensity, improving functioning and sleep quality in patient with piriformis syndrome. both these techniques are passive, non-invasive manual therapy techniques which are easy to perform and less time consuming and may yield better outcomes resulting improved quality of life.


Eligibility criteria:
inclusion criteria: 1. age group 25-55 years 2. both male and female. 3. gluteal pain with or without radicular symptoms. 4. patients of piriformis syndrome diagnosed by orthopedic consultant. 5. sub-acute and chronic piriformis syndrome. 6. unilateral pain. 7. pain score equal to and greater than 3 according to pain rating scale. exclusion criteria: 1. intermittent vascular claudication and spondylolisthesis. 2. past history of hip, femur or vertebral fracture 3. past history of spinal surgery. 4. spinal tuberculosis. 5. rheumatoid disease. 6. disc pathology, sacroiliac joint dysfunction or mechanical back pain. 7. history of infectious disease. 8. leg length discrepancy. 9. any postural abnormality or deformity.

Keywords: function, pain,hold relax ,sleep quality, mobilization
expression of hoxa10 and hoxa11 in the endometrium of infertility patients with an endometrial polyp before and after polypectomy

Conditions: Infertility

Summary: the aim of this study is to measure the expression of hoxa10 and hoxa11 in the endometrium of infertility patients with an endometrial polyp before and after polypectomy. hoxa10 and hoxa11 are well-established markers of implantation. it is uncertain as to whether an endometrial polyp interferes with embryo implantation. a higher expression of hoxa10 and hoxa11 after polypectomy can indicate that endometrial polyp does interfere with embryo implantation.


Eligibility criteria:
inclusion criteria: * infertile women with endometrial polyp exclusion criteria: * endometriosis * polycystic ovary syndrome * hydrosalpinx * sub-mucus myoma * women who have taken hormonal therapy in the preceding month
health coaching-based navigation at the conclusion of treatment for the support of black breast cancer survivors

Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8

Summary: this clinical trial evaluates the feasibility of coaching-based navigation for black breast cancer survivors including recruitment, dropout, and survey completion rates. a coaching-based navigation may perform a needs assessment and coach the participant to access relevant supportive content including physical rehabilitation, emotional and psychosocial support, and nutrition and exercise programming. this trial aims to see whether this navigation program may improve the quality of life of black breast cancer survivors.

primary objective: i. to evaluate the feasibility of coaching-based navigation for black breast cancer survivors including recruitment, dropout, and survey completion rates. secondary objectives: i. to evaluate the preliminary impact of health coaching on completion of scheduled survivorship related referrals and participation in support services. ii. to determine the preliminary impact on quality of life and self-efficacy pre and post coaching. outline: patients are assigned a black patient navigator for racial concordance and receive coaching from patient navigator over 30 minutes every other week for 3 months and then monthly for 3 months.

Eligibility criteria:
inclusion criteria: * black women \> 18 years of age with stage i-iii primary breast cancer who have completed definitive breast cancer treatment
saliva modification related to fat perception in human

Conditions: Fat Sensitivity

Summary: the perception of fat represents major scientific and nutritional issues. this research aims to identify salivary markers that could predict and possibly explain this perception in healthy human being. this would help to develop nutritional strategies for a more rational consumption of fat.


Eligibility criteria:
inclusion criteria: * male * 18-60 years exclusion criteria: * female * non healthy
breaking sitting and metabolic health in sedentary overweight and obese adults

Conditions: Metabolic Health; Gut Hormones; Energy Balance

Summary: the purpose of this project is to investigate the effects of breaking up prolonged sitting on postprandial metabolic responses, gut hormones secretion and energy balance in sedentary overweight and obese adults.

two trials are included in this project - prolonged sitting and breaking sitting. in the prolonged sitting trial, after consuming breakfast, participants sat on a chair for 180 min. after 180 min, lunch was provided. after finishing lunch, participants sat on a chair for another 120 min. in the breaking sitting trial, after consuming breakfast, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. for the remainder of the time participants sat on the chair. after 180 min, lunch was provided. after finishing lunch, participants continued 2 min of walking every 20 min for the following 120 min. blood samples were collected in a regular pattern throughout the trials. energy balance (e.g., energy intake and spontaneous physical activity) was assessed using food diary and an accelerometer until midnight in the trial days once participants left laboratory.

Eligibility criteria:
inclusion criteria: * physical inactive males and females * aged between 20 and 45 years * overweight and obese healthy adults (waist circumference greater than 90 cm for males and 80 cm for females) * weight stable for more than 3 months (no change in weight +/- 3%) * non-smoker * able to walk comfortably on a treadmill exclusion criteria: * personal history of/existing diabetes, cardiovascular disease, metabolic disease or dyslipidaemia * waist circumference \< 90 cm for male and \< 80 cm for female * taking medications that may influence lipid or carbohydrate metabolism or immune system function * unable to take part in exercise for any reason (e.g., injury or disability) or a positive response to any questions on the physical activity readiness questionnaire (par-q)

Keywords: glp-1 pyy breaking sitting energy balance postprandial glycaemia